Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
23 Oct 2025

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia
ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )
20 Oct 2025

Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
20 Oct 2025

Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA
Zanzalintinib plus atezolizumab improves survival in refractory mCRC ( Dr Anwaar Saeed - University of Pittsburgh, Pittsburgh, USA )
20 Oct 2025

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Oct 2025

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Oct 2025

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )
19 Oct 2025

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others ( Dr Emerik Österlund - MD Anderson Cancer Center, Houston, USA )
18 Oct 2025

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

Dr Arvind Dasari - MD Anderson Cancer Center, Houston, USA
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer ( Dr Arvind Dasari - MD Anderson Cancer Center, Houston, USA )
8 Oct 2025

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer ( Dr Elena Élez - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
18 Aug 2025

Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC

Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC ( Dr Scott Kopetz - MD Anderson Cancer Center, Houston, Texas )
17 Jul 2025